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A common target in carcinogenesis is de-regulation of controlled
G1-S phase progression of the cell cycle (Palmero and Peters,
1996). Thus during tumourigenesis the genes encoding proteins
that regulate progression through G1, frequently undergo genetic
alterations. In dividing cells, the cyclin D1 gene (CCND1) acts as
a growth factor sensor that responds to mitogenic signals to
promote cellular proliferation. This is achieved through binding of
cyclin D1 protein to specific cyclin-dependent kinases (cdk4 and
cdk6). The cdk–cyclin D1 complex catalyses the phosphorylation
of the retinoblastoma protein (pRB). In a hyperphosphorylated
form pRb is inactivated and cells are released from G1 arrest and
progress into S phase (Sherr, 1996).
In many cancers CCND1 expression is de-regulated leading to
overexpression of cyclin D1 protein. This can occur through
several mechanisms. For example, in some parathyroid adenomas
an inversion involving 11q13 and 11q15 results in CCND1 expres-
sion coming under the control of the parathyroid hormone gene
promoter (Motokura et al, 1991). In B-cell malignancies,
including centrocytic B-cell lymphomas, CCND1 expression is
de-regulated under the influence of the immunoglobulin heavy
chain enhancer as a result of a reciprocal chromosomal transloca-
tion at the BCL1 breakpoint t(11;14)(q13;q32) (de Boer et al,
1993, 1995). Amplification of CCND1 has been described in other
tumours including those of the head and neck, breast, lung,
bladder, pancreas and liver (Callender et al, 1994; Gillett et al,
1994; Nishida et al, 1994; Betticher et al, 1996; Bringuier et al,
1996; Gansauge et al, 1997).
Rearrangement of the CCND1 locus resulting in protein over-
expression has been associated with prognosis in a variety of
malignancies. In head and neck cancers, CCND1 amplification,
and protein overexpression correlates with poor prognosis
(Michalides et al, 1994; Bellacosa et al, 1996). In contrast, cyclin
D1 overexpression has been shown to correlate with good prog-
nosis in non-small-cell lung cancer (NSCLC), breast cancer and
bladder cancer (Betticher et al, 1996; Bringuier et al, 1996;
Gillett et al, 1996). Thus a better understanding of the process of
de-regulation of the control of CCND1 expression should help
reveal mechanisms of carcinogenesis and also identify prognostic
indicators. Most studies examining the expression of cyclin D1 in
tumours have used immunohistochemistry (IHC) with monoclonal
antibodies to detect the protein on paraffin-embedded tumour
sections. Cyclin D1 has been detected predominantly in the
nucleus, though cytoplasmic localization of protein has been
described in non-Hodgkin’s lymphoma (NHL), NSCLC and some
breast carcinomas (Nakamura et al, 1994, Betticher et al, 1996,
Gillett et al, 1996).
Ovarian cancer has a very poor prognosis with an average
5-year survival of only 30% (Chang et al, 1994). Most patients
present with unresectable, advanced disease and are candidates
for chemotherapy. Some of these patients demonstrate markedly
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improved survival following chemotherapy, whilst others fail to
respond or develop chemoresistance. Clearly, there is a need for a
greater understanding of the mechanisms involved in disease
pathogenesis to allow development of preventive strategies as well
as prognostic markers that could be used in patient management.
Recent studies using Western analysis have shown that cyclin D1
is overexpressed in the majority of malignant ovarian tumours but
is absent in benign lesions (Barbieri et al, 1997). In this analysis
the subcellular localization of cyclin D1 was not determined. IHC
studies have shown overexpression of cyclin D1 protein in up to
28% of malignant ovarian tumours, suggesting deregulation of
cyclin D1 to be important in a sub-group of patients with the
disease (Hung et al, 1996; Worsley et al, 1997). In these works
only nuclear immunostaining of cyclin D1 was scored. In a pilot
study we have found cytoplasmic localization of cyclin D1 in a
high proportion of ovarian tumours (Dhar et al, 1997).
Accordingly, we have extended this analysis to examine the
frequency and subcellular localization of cyclin D1 in epithelial
ovarian cancer from 81 cases. In addition we have investigated the
mechanism leading to de-regulation of cyclin D1 expression and
determined whether overexpression of the protein is associated
with clinical outcome in women with the disease.
MATERIALS AND METHODS
Patient characteristics and materials
Eighty-one Northern European Caucasian women with histo-
logically confirmed epithelial ovarian cancer were recruited with
Ethics Committee approval and informed consent from the North
Staffordshire Hospital. These patients have been described in
detail (Howells et al, 1998). Tumours were staged by the criteria of
the International Federation of Gynaecologists and Obstetricians
(FIGO). Histological type and grade were assigned by one
specialist pathologist (CM). Survival is defined as the time
between diagnosis and death or the time at which the patient was
last seen. Progression-free interval (PFI) is defined as the time
interval between diagnosis and the occurrence of an event (death,
recurrence, or progression of disease), or the last time the patient
was seen. Paraffin-embedded ovarian tumour tissue was also
obtained. Solid tumour material was collected at time of surgery,
snap-frozen in liquid nitrogen and stored at –70°C. Blood samples
were collected in EDTA and stored at –20°C.
Immunohistochemistry
Immunohistochemistry was carried out using a Shandon sequenza
(Shandon Scientific Limited, Cheshire, UK) with a modification
of the method described by Betticher et al (1996). Briefly,
formalin-fixed paraffin sections were air-dried on 2% 3-amino-
propyltriethoxysilane-coated (Sigma, Dorset, UK) slides. After
dewaxing in xylene, the sections were treated with freshly
prepared 3% hydrogen peroxide in methanol for 5 min in order to
block endogenous peroxidase activity and rinsed thoroughly in
phosphate-buffered saline (PBS) pH 7.2. The sections were
then microwaved for 4 ´ 5 min in EDTA buffer (pH 8.0).
Immunohistochemistry was performed using Vectastatin
Universal Elite ABC kit (Vector Laboratories, UK). A mouse
monoclonal cyclin D1 antibody (DCS-6; Novocastra, Newcastle
Upon-Tyne, UK) was used at 1:25 dilution and sections were incu-
bated for 1 h at room temperature. Detection was performed using
freshly prepared diaminobenzene (Sigma) at room temperature
for 5 min. Sections were counter-stained with haematoxylin,
dehydrated and mounted. Controls were provided by a cyclin D1
positive breast cancer section, negatives by omitting primary
antibody and including a normal ovary section. Both nuclear
and cytoplasmic staining were recorded. Slides were graded as:
negative (0–<10% cells stained), + (>10%–<50% cells stained),
++ (>50%–<75% cells stained) and +++ (>75% cells stained).
Staining was interpreted independently by KD and PH.
Western analysis
Ovarian tissue was disrupted using an Omnigene homogenizer
and proteins were extracted using standard procedures (Sambrook
et al, 1989). Protein concentrations were estimated using the
Bio-Rad Protein assay kit with bovine serum albumin (BSA) as
the standard. Tissue homogenates (20 mg protein) were separated
on 10% polyacrylamide gels in the presence of sodium dodecyl
sulphate (SDS). Proteins were transferred by electroblotting onto
polyvinyldifluoride (PVDF) membrane (Amersham, Bucking-
hamshire, UK). Following transfer, filters were blocked in 1%
BSA (Sigma) in PBS-T (PBS containing 0.05% Tween-20) for 1 h
at room temperature and subsequently washed twice in PBS-T.
Blots were incubated with cyclin D1 monoclonal antibody (clone
105 Transduction Laboratories, Lexington, KY, USA) at 1:250 in
PBS-T for 1 h at room temperature. Filters were rinsed three times
for 5 min in PBS-T and were then incubated with 1:1000 dilution
of horseradish peroxidase-conjugated rabbit anti-mouse IgG
secondary antibody (Dako Ltd, Cambridge, UK). Following three
5-min washes in PBS-T, cyclin D1 protein was visualized using
the super signal substrate (Pierce, Chester, UK). Molecular weight
markers (molecular weight standard mixture 29–205 kDa) and
glyceraldehyde 3-phosphate dehydrogenase (36 kDa) were used
as references for protein size (Sigma). Filters were stripped
following the manufacturer’s recommendations (Hybond-P, PVDF
membrane, Amersham) and re-probed with a monoclonal antibody
to vinculin (Sigma) to assess protein loading.
DNA extraction
DNA was extracted from paraffin sections (5 mm) using a genomic
DNA extraction kit (Scotlab, Strathclyde, UK). High molecular
weight DNA was extracted from frozen ovarian tissue and
peripheral blood using a phenol–chloroform method as described
by Sambrook et al (1989).
PCR analysis of CCND1
Imbalances within CCND1 were assessed by restriction fragment
length polymorphism polymerase chain reaction (RFLP-PCR)
analysis using polymorphisms in exon 4 and the 3¢ UTR region of
the gene as described by Betticher et al (1995, 1996). Briefly, PCR
products were digested with restriction enzymes to reveal the
polymorphic alleles; HaeIII (New England Biolabs, Hertfordshire,
UK) for the 3¢UTR polymorphism and ScrFI (New England
Biolabs) for the exon 4 polymorphism. Digests were visualized on
3% agarose gels stained with ethidium bromide. Multiplex PCR
was a modification of the method previously described (Betticher
et al, 1996). The CCND1 gene (chromosome 11q13) was
compared to the adenosine deaminase (ADA) gene (chromosome
20q12–13). The following primers were used to amplify regions of1176 KK Dhar et al
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the genes; CCND1; forward, 5¢ATATTCCGTAGGTAGATGTG-
TAAC3¢ and reverse, 5¢TGTCACTATTTCGTCTTCTC3¢. ADA;
forward, 5¢GCGGGTGAACGTCAATGTGTT3¢, and reverse,
5¢GTGTCCAGGGTGGACTTGAAG3¢. Multiplex PCR was per-
formed in 100-ml volumes containing 1 ´ Taq polymerase buffer
(Promega UK Ltd, Southampton, UK), a total of 100 mM dNTPs,
0.5 mg of each CCND1 primer and 0.05 mg of each ADA primer,
0.5 mg of genomic DNA and 2 U Taq polymerase (Promega).
Reactions were cycled 28 times on an automated PCR machine.
Products were visualized on 3% agarose gels stained with
ethidium bromide. CCND1 allelic imbalance/gene amplification
was determined visually by comparison to normal control DNA
samples and the A431 cell line which displays a five-fold level of
amplification of CCND1 (Kurzrock et al, 1995).
Statistical analysis
Statistical analysis was performed using Stata, version 5 (Stata
Corporation, Texas). Pearson-c2 tests were used to identify
differences between staining patterns and the clinico-pathological
parameters. A Cox’s proportional hazard regression model was
used in the analysis of the effects of cyclin D1 staining on PFI
and survival using univariate analysis. Multivariate analysis was
used to correct for any potential confounding factors (e.g. age).
Kaplan–Meier curves were generated for graphical representation
of survival. A probability level of 5% was considered statistically
significant.
RESULTS
IHC analysis of cyclin D1 expression and localization
Overexpression of cyclin D1 protein was detected in 72/81 (89%)
of the epithelial ovarian cancers examined. The level of over-
expression was variable between tumours and was graded accord-
ingly (Table 1). Cyclin D1 was detected predominantly in the
nuclei of tumour cells in 7/81 (9%) of the cases, and simultane-
ously in the nucleus and cytoplasm of tumours in 17/81 (21%).
Thus 24/81 (30%) of the tumours examined displayed nuclear
expression of cyclin D1. However, in 48/81 (59%) of the tumours
examined expression was restricted to the cytoplasm of the tumour
cells. Representative examples of simultaneous nuclear and cyto-
plasmic (Figure 1 A, B) and exclusively cytoplasmic staining
(Figure 1 C, D) are shown. Paraffin sections obtained from normal
ovarian tissue did not demonstrate cyclin D1 immunostaining
(Figure 1 E).
Western analysis of cyclin D1 expression
To investigate the specificity of the observed cytoplasmic staining
for cyclin D1, we performed Western analysis and determined the
size of the cross-reacting protein. Western blotting for cyclin D1
expression was performed on proteins extracted from 11 malignant
tumours and two benign cysts snap-frozen at surgery. The mono-
clonal antibody clone 105 (Transduction Laboratories) was used to
detect cyclin D1. A 36 kDa cyclin D1 protein was detected in 7/7
tumours displaying exclusively cytoplasmic immunostaining of
cyclin D1 and 1/1 tumour displaying simultaneous nuclear with
cytoplasmic immunostaining. Cyclin D1 was not detected in 3/3
malignant tumours negative for immunostaining (data not shown)
and 2/2 benign ovarian cysts. Representative examples of cyclin
D1 expression detected by Western blotting in malignant tumours
displaying nuclear and cytoplasmic immunostaining, and exclu-
sively cytoplasmic immunostaining are shown in Figure 2. The
level of cyclin D1 expression varied between tumours when
compared to the intensity of the vinculin blots.
Analysis of CCND1 amplification in tumours
overexpressing cyclin D1 protein
The mechanism leading to de-regulation of cyclin D1 protein
expression in ovarian tumours was investigated. Tissue from 33
tumours displaying overexpression of cyclin D1 protein was avail-
able for DNA and was assessed for amplification of CCND1.
Using multiplex and/or RFLP-PCR techniques on the same
sample, information was available on CCND1 amplification in 29
of the tumours. Amplification of CCND1 was detected in 1/29 of
these tumours. Amplification was assessed qualitatively by
comparison of the intensity of ethidium bromide staining of PCR
products in tumours with normal controls and the A431 vulval
carcinoma cell line (Figure 3 A, B) which has a reported fivefold
amplification of CCND1 (Kurzrock et al, 1995). A representation
of allele imbalance detected by RFLP-PCR analysis and amplifica-
tion of CCND1 detected by multiplex PCR is shown (Figure 3
A,B). Tumour 323 displayed allele imbalance for CCND1 HaeIII
(Figure 3A, lane 6). This was confirmed as CCND1 amplification
by multiplex PCR (Figure 3B, lane 3). However 5/26 tumours
informative for either or both of the CCND1 polymorphisms
displayed allele imbalance in the absence of multiplex-PCR imbal-
ances. For example, tumour 51 displayed imbalance of a CCND1
allele using RFLP-PCR for the CCND1 HaeIII and ScrFI poly-
morphisms (Figure 3A, lanes3 & 4 and 9 & 10), but displayed no
imbalance with multiplexPCR (Figure 3B, lane 2). These tumours
Table 1 Cyclin D1 expression and localization in ovarian cancers
Cyclin D1 level of staining
0 + ++ +++ Total
Negative 9 (11.1) 0 (0) 0 (0) 0 (0) 9 (11.1)
Positive
Nucleara 0 (0) 1 (1.2) 2 (2.5) 4 (4.9) 7 (8.6)
Nuclear/cytoplasmicb 0 (0) 3 (3.7) 10 (12.3) 4 (4.9) 17 (21)
Cytoplasmic only 0 (0) 24 (29.6) 12 (14.8) 12 (14.8) 48 (59.2)
Total 9 (11.1) 28 (34.6) 24 (29.6) 20 (24.7) 81 (100)
Numbers in parentheses are %. aPredominantly nuclear staining with some diffuse cytoplasmic localization. bSimultaneous nuclear and cytoplasmic
immunostaining. Stained sections were graded as negative (0–<10% cells stained), + (>10%–<50% cells stained), ++ (>50%–<75% cells stained)
and +++ (>75% cells stained).Cyclin D1 in epithelial ovarian tumours 1177
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were interpreted as displaying allele imbalance at the CCND1
locus, which may be as a result of LOH of a CCND1 allele.
Association of IHC staining of cyclin D1 with tumour
characteristics
To investigate whether cyclin D1 protein overexpression and
subcellular localization was associated with prognosis, the IHC
data was compared with tumour and patient characteristics.
Cytoplasmic and nuclear expression of cyclin D1 protein was
detected in both borderline and invasive tumours. No significant
difference was found in the number of tumours staining positive
for cyclin D1 or the subcellular localization of the protein when
compared with tumour differentiation and FIGO stage (Table 2).
However, a significant difference (P = 0.0137) in the distribution
of immunostaining for cyclin D1 was observed when compared
with tumour histology (Table 2). In addition, within tumours
expressing cyclin D1 (n = 72), cytoplasmic localization occurred
in a higher proportion of serous compared with non-serous
tumours (Fisher exact test; P = 0.004, OR 4.84, 95% CI
1.42–19.12).
Association of IHC staining of cyclin D1 with clinical
outcome
We compared the expression of cyclin D1 with clinical outcome
in 79 patients in whom clinical follow-up data was available
(Howells et al, 1998). Using Cox’s proportional hazards model
we found no significant correlation between expression and
subcellular localization of cyclin D1 when compared with
progression-free interval (PFI) and overall survival (Figure 4).
We also compared the level of expression (neg. & + vs ++ & +++)
with PFI and overall survival. The median PFI (23 months vs 23.2
months) and median survival (35 months vs 40.4 months) within
these two groups were not significantly different (data not
shown).
DISCUSSION
We have used IHC to detect cyclin D1 overexpression in 81
epithelial ovarian cancers. We found a large proportion of the
tumour studied demonstrated overexpression of cyclin D1 protein.
Expression was not detected in histologically normal ovarian
tissue or benign ovarian cysts. In over half of the tumours
expressing cyclin D1, the protein was localized exclusively in the
cytoplasm of the cells. Overexpression of cyclin D1 as determined
by IHC, has previously been described in ovarian tumours (Hung
et al, 1996; Worsley et al, 1997). Hung et al reported overexpres-
sion in 28% of cases examined using a polyclonal cyclin D1 anti-
body whilst Worsley et al detected overexpression of cyclin D1 in
up to 26% of tumours using a mouse monoclonal antibody (mAb).
The lower number of cases overexpressing cyclin D1 reported in
these earlier studies may reflect that only nuclear expression of
cyclin D1 was scored. In our series, nuclear expression of cyclin
D1 occurs in 30% of ovarian tumours which compares favourably
with previous reports.
A B
Figure 1 Immunohistochemical analysis of cyclin D1 expression in epithelial ovarian cancers. Simultaneous nuclear and cytoplasmic localization of cyclin D1
visualized under (A) low (´10 objective) and (B) high (´40 objective) magnification. Cytoplasmic localization of cyclin D1 visualized under (C) low and (D) high
magnification. Normal ovarian tissue stained for cyclin D1 expression under low magnification (E)
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Figure 2 Expression of cyclin D1 (36 kDa) protein in epithelial ovarian tumours. Lysates from malignant tumours displaying cytoplasmic (lanes 1, 3 & 4) and
nuclear/cytoplasmic (lane 2) expression of cyclin D1 (as determined by IHC) are shown. Lane 5 contains lysate extracted from a benign ovarian cyst.
Membranes were probed with: (A) monoclonal antibody for cyclin D1, the position of the 36 kDa protein is shown left; (B) levels of protein loading were
visualized by stripping the membrane and re-probing with a monoclonal antibody for vinculin
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Figure 3 Analysis of CCND1 amplification in ovarian tumours. (A) RFLP-PCR analysis of CCND1; PCR products were digested with ScrFI (lanes 2–7) or
HaeIII (lanes 8–11) and separated on 3% agarose gels stained with ethidium bromide. Lane 1; ØX 174 HaeIII digest, lane 2; normal lymphocytes, lane 3;
lymphocytes patient 51, lane 4; tumour patient 51, lane 5; normal lymphocytes patient 323, lane 6; tumour patient 323, lane 7; A431. Lane 8; normal
lymphocytes, lane 9; normal lymphocytes patient 51, lane 10; tumour patient 51, lane 11; A431. (B) Multiplex PCR analysis of ovarian tumours to determine
amplification of CCND1. PCR products for CCND1 and ADA, shown left were separated on 3% agarose gels. Lane 1; A431 DNA, lane 2; tumour 51, lane 3;
tumour 323, lane 4; normal lymphocytes, lane 5; ØX 174 HaeIII digest
Table 2 Association of cyclin D1 expression with ovarian tumour characteristics
Cyclin D1 immunostaining
Nuclear Cytoplasmic Negative
n = 24 (29.6) n = 48 (59.2) n = 9 (11.1)
Age at diagnosis (years)
Range 36–74 28–90  46–80 
Median 59.5 61.5 74 
Tumour differentiation
Borderline 2 (25.0) 5 (62.5) 1 (12.5)
Well 4 (57.1) 3 (42.9) 0 (–)
Moderate 10 (33.3) 17 (56.7) 3 (10)
Poor 5 (28.8) 15 (62.5) 4 (16.7)
Not mentioned 3 (25.0) 8 (66.7) 1 (8.3)
FIGO stage
I 11 (42.3) 14 (53.9) 1 (3.8)
II 2 (22.2) 6 (66.7) 1 (11.1)
III 9 (22.5) 24 (60.0) 7 (17.5)
IV 2 (33.3) 4 (66.7) 0 (–)
Histology
Endometroid 7 (50) 6 (42.9) 1 (7.1)
Serousa 5 (13.5) 27 (73.0) 5 (13.5)
Clear cell 4 (36.3) 6 (54.6) 1 (9.1)
Mucinous 6 (46.2) 7 (53.8) 0 (–)
Other/Mixed 2 (33.3) 2 (33.3) 2 (33.3)
Figures in parenthesis are %. aThe distribution of immunostaining in serous tumours was significantly
different compared with other histological types. (Fisher exact test, P = 0.0137, c2
2 = 8.44).
BRecently using Western analysis, cyclin D1 protein was detected
in 90% of the malignant ovarian tumours examined (Barbieri et al,
1997). The high level of cyclin D1 overexpression in this study
compared with previous findings (Hung et al, 1996; Worsley et al,
1997) may reflect differences in sensitivity of detection of Western
blotting compared with IHC. However, Barbieri et al did not deter-
mine subcellular localization of the protein, which prompted us to
consider the significance of cytoplasmic staining for cyclin D1. To
investigate the specificity of cytoplasmic immunostaining of
cyclin D1, we used Western analysis of extracted proteins from
tumours demonstrating overexpression of cyclin D1. We used a
different cyclin D1 mAb for the Western analysis (clone 105) than
that used for IHC (clone DCS-6). Both antibodies identify a 36
kDa protein in Western analysis of a panel of cell lines (data not
shown), although in our hands DCS-6 is not as specific as clone
105 in Western blots on ovarian tumour material. Furthermore,
clone 105 was not suitable for IHC. Analysis of tumours
displaying exclusively cytoplasmic overexpression of cyclin D1
and a tumour displaying simultaneous nuclear and cytoplasmic
expression revealed a 36 kDa band with clone 105. We were
unable to detect expression of cyclin D1 by Western analysis in
three tumours negative by IHC, as well as benign ovarian cysts.
Together the IHC and Western data consolidate our findings of
frequent cytoplasmic overexpression of cyclin D1 in our cohort of
tumours. It is possible, however, that the two antibodies may
recognize different cyclin D1 epitopes and further may hybridize
to other cyclin D1 protein variants. It has been shown that CCND1
mRNA is alternatively spliced (Betticher et al, 1995) and that
DCS-6 recognizes both proteins encoded from the alternate
transcripts in vitro expression studies (Sawa et al, 1998). Future
studies including immunoprecipitation experiments are needed to
further characterize cytoplasmic cyclin D1 protein in ovarian
tumours.
In many cancers overexpression of cyclin D1 protein is associ-
ated with tumour characteristics and clinical outcome. The local-
ization of the cyclin D1 protein may have implications for the
diagnosis and prognosis in cancer. In NHL localization of cyclin
D1 has been implicated in patient prognosis (Nakamura et al,
1994). Thus in mantel cell lymphomas (MCL), generally associ-
ated with poor prognosis, frequent chromosomal translocation
t(11;14)(q13;q32) leads to strong nuclear overexpression of cyclin
D1 protein and distinguishes the malignancy from other types of
NHL (Nakamura et al, 1994; de Boer et al, 1995). Nakumura et al
also describe a pattern of cytoplasmic immunoreactivity in diffuse
B-cell and follicular B-cell NHL which are prognostically
different to MCL. In ovarian cancers, we found no correlation
between overexpression and localization of cyclin D1 protein with
tumour stage or differention. However, cytoplasmic localization of
cyclin D1 protein occurred more frequently in serous compared
with non-serous tumours. A correlation between nuclear expres-
sion of cyclin D1 and well-differentiated and borderline malig-
nancy in a series of 43 ovarian tumours has been described
(Worsley et al, 1997). The differences of our findings may reflect
the larger number of tumours studied. We did not find any signifi-
cant associations between cyclin D1 overexpression and sub-
cellular localization with PFI and overall survival of patients. It
has been shown that overexpression of cyclin D1 mRNA in epithe-
lial ovarian cancers does not correlate with clinical outcome
(Masciullo et al, 1997); however, to date no study has examined
expression of cyclin D1 protein with clinical outcome.
The mechanism of cyclin D1 protein overexpression in ovarian
cancer is unclear. Amplification of CCND1 in ovarian tumours is
infrequent (Courjal et al, 1996; Masciullo et al, 1997); however, in
these studies cyclin D1 protein levels were not measured. We
examined  CCND1 amplification in tumours overexpressing cyclin
D1 protein as determined by IHC; 28/29 of these tumours did not
demonstrate amplification of CCND1. However, 5/24 of the
tumours displayed allele imbalance of CCND1 using RFLP-PCR,
but an absence of imbalance of CCND1 using PCR multiplex
analysis. These findings may result from LOH at the CCND1 locus
in these tumour cells. High levels of LOH at 11q have been pre-
viously described in epithelial ovarian cancers though there is no
evidence to suggest that CCND1 is the target of the LOH in this
region (Foulkes et al, 1993; Gabra et al, 1996). Overexpression of
cyclin D1 in the absence of gene amplification has been reported
in NSCLC and breast cancer (Gillett et al, 1994; Betticher et al,
1996). Clearly mechanisms other than CCND1 amplification may
lead to overexpression of cyclin D1 protein. To date no in vivo
abnormalities to CCND1 have been described that influence intra-
cellular localization of the protein. In vitro mutations to CCND1
have been shown to influence the localization of cyclin D1–cdk4
protein complexes to the cytoplasm in mouse cells (Diehl and
Sherr, 1997). In this study, nuclear localization could be achieved
through overexpression of the cdk inhibitor p21. It has been
suggested that cdk inhibitors including p21 may have additional
roles as adaptor proteins involved in the assembly and intracellular
Cyclin D1 in epithelial ovarian tumours 1179






















































































Figure 4 Kaplan–Meier survival plots showing the association between
cyclin D1 expression and (A) progression-free interval and (B) survival, in
patients with epithelial ovarian cancerlocalization of kinase complexes (LaBaer et al, 1997). No muta-
tions in CCND1 coding sequences were found in NSCLC cells
displaying cytoplasmic only expression (Betticher et al, 1995). It
is possible however that localization of cyclin D1 to the cytoplasm
in ovarian tumours results from mutations to other genes encoding
proteins with which it complexes.
Understanding the function of cytoplasmic cyclin D1 in ovarian
tumours may be important clinically. In the nucleus cyclin D1
facilitates cell cycle progression. Thus overexpression of cyclin
D1 protein in vitro is associated with increased proliferation
(Quelle et al, 1993; Musgrove et al, 1994). However, paradoxi-
cally, cyclin D1 overexpression has also been associated with
apoptosis (Kranenburg et al, 1996; Kotelnikov et al, 1997) and
cellular senescence (Dulic et al, 1993; Lucibello et al, 1993). The
function of cytoplasmic cyclin D1 described in this study has not
been addressed. However, it would be interesting to investigate
the expression of cdk4 or the status of pRB in these tumours. In
addition a cytoplasmic substrate for cdk4 and cdk6 has been
described (Kwon et al, 1995). Furthermore, although predomi-
nantly nuclear during the G1 phase of the cell cycle, cyclin D1 and
D2 in dividing U-2-OS cells demonstrate cytoplasmic localization
at G1/S transition (Lukas et al, 1994).
In conclusion, overexpression of cyclin D1 leading to cyto-
plasmic and nuclear protein localization is a frequent event in
ovarian cancer occurring mainly in the absence of CCND1
amplification. A better knowledge of the mechanisms involved in
deregulation of cyclin D1 expression and the biological con-
sequence of this, may ultimately lead to the development of
improved strategies for the treatment of ovarian cancer.
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